ALIMERA SCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS
ILUVIEN® Revenue Growth in Europe Continues
$37.5 Million Private Placement Completed to Expand ILUVIEN Commercialization
Alimera Will Host a Conference Call at 4:30 PM ET Today
ATLANTA, GA, February 27, 2014 — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.
“This is an exciting time for Alimera. We made significant commercial progress with ILUVIEN® during the fourth quarter of 2013 in Germany and the United Kingdom, and entered into labeling discussions with the U.S. Food and Drug Administration,” said Dan Myers, president and chief executive officer of Alimera Sciences. “We grew total revenue more than 23% on a sequential basis, primarily through sales of ILUVIEN in Germany, despite the holiday seasonality effect and market access constraints during the fourth quarter.”
“We also received positive final guidance for ILUVIEN from the U.K.’s National Institute for Health and Care Excellence, ultimately expanding patient access to ILUVIEN through the National Health Service in England and Wales. Initial shipments have been made to several National Health Service facilities, with the first patient receiving an ILUVIEN implant in January 2014,” Mr. Myers continued. “Additionally, the Scottish Medicines Consortium, after completing its assessment and review of a simple patient access scheme, accepted ILUVIEN for restricted use within the National Health Service Scotland, providing expanded access in the U.K. to patients suffering from chronic DME.”
The following information was filed by Alimera Sciences Inc (ALIM) on Thursday, February 27, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alimera Sciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Alimera Sciences Inc.
Ticker: ALIM CIK: 1267602 Form Type:10-K Annual Report Accession Number: 0001267602-14-000015 Submitted to the SEC: Thu Mar 06 2014 6:05:42 PM EST Accepted by the SEC: Fri Mar 07 2014 Period: Tuesday, December 31, 2013 Industry: Pharmaceutical Preparations